Bavarian Nordic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.08.22	Bavarian Nordic Announces First Half 2022 Results (GlobeNewswire)
23.08.22	Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher (finanzen.net)
18.08.22	Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines (GlobeNewswire)
09.08.22	Erste Schätzungen: Bavarian Nordic informiert über die jüngsten Quartalsergebnisse (finanzen.net)
03.08.22	Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023 (GlobeNewswire)
27.07.22	Bavarian Nordic Receives U.S. and EU Approvals of its Fill and Finish Vaccine Manufacturing Facility (GlobeNewswire)
25.07.22	Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox (GlobeNewswire)
22.07.22	Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox (GlobeNewswire)
19.07.22	Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023 (GlobeNewswire)
18.07.22	Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox Outbreak (GlobeNewswire)
15.07.22	U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic (GlobeNewswire)
01.07.22	U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic (GlobeNewswire)
28.06.22	Bavarian Nordic Announces Grant of PRIME Eligibility from the European Medicines Agency for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults (GlobeNewswire)
16.06.22	Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate (GlobeNewswire)
14.06.22	Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak (GlobeNewswire)
10.06.22	Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government (GlobeNewswire)
07.06.22	Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of Canada (GlobeNewswire)
03.06.22	Bavarian Nordic Conference Call: General Monkeypox Update (GlobeNewswire)
30.05.22	Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox Outbreak (GlobeNewswire)
25.05.22	Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox Outbreak (GlobeNewswire)
19.05.22	Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases (GlobeNewswire)
18.05.22	Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government (GlobeNewswire)
09.05.22	Bavarian Nordic Announces Interim Results for the First Three Months of 2022 (GlobeNewswire)
08.05.22	Ausblick: Bavarian Nordic gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
05.05.22	Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate (GlobeNewswire)
04.05.22	Bavarian Nordic to Host First Quarter 2022 Results Conference Call and Webcast (GlobeNewswire)
24.04.22	Erste Schätzungen: Bavarian Nordic veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
20.04.22	Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults (GlobeNewswire)
21.03.22	Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian M (GlobeNewswire)
04.03.22	Bavarian Nordic Publishes Annual Report 2021 (GlobeNewswire)
03.03.22	Ausblick: Bavarian Nordic stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
28.02.22	Bavarian Nordic to Host Full Year 2021 Results Conference Call (GlobeNewswire)
28.02.22	Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial (GlobeNewswire)
17.02.22	Erste Schätzungen: Bavarian Nordic stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
14.02.22	Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults (GlobeNewswire)
19.01.22	Bavarian Nordic Appoints Russell Thirsk as new Chief Operating Officer (GlobeNewswire)
06.12.21	Bavarian Nordic A/S Announces Completion of Directed Issue of 6,373,680 New Ordinary Shares (GlobeNewswire)
06.12.21	Bavarian Nordic A/S Launches Offering of up to 6,373,680 New Shares in a Directed Issue (GlobeNewswire)
06.12.21	Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base (GlobeNewswire)
05.12.21	Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate (GlobeNewswire)
12.11.21	Bavarian Nordic Announces Interim Results for the First Nine Months of 2021 (GlobeNewswire)
11.11.21	Ausblick: Bavarian Nordic präsentiert Quartalsergebnisse (finanzen.net)
05.11.21	Bavarian Nordic to Host Third Quarter 2021 Results Conference Call (GlobeNewswire)
24.09.21	Bavarian Nordic’s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament (GlobeNewswire)
01.09.21	Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate (GlobeNewswire)
25.08.21	Bavarian Nordic Announces First Half 2021 Results (GlobeNewswire)
23.08.21	Bavarian Nordic Receives Funding from the Danish Ministry of Health to Advance the Development of COVID-19 Booster Vaccine (GlobeNewswire)
23.08.21	Ausblick: Bavarian Nordic mit Zahlen zum abgelaufenen Quartal (finanzen.net)
23.08.21	Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine (GlobeNewswire)
18.08.21	Bavarian Nordic to Host First Half 2021 Results Conference Call and Webcast (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	74.24	0.27 %	K V
Swisscom	507.50	0.20 %	K V
CieFinRichemont	138.45	-0.04 %	K V
Swiss Re	131.10	-0.27 %	K V
Sika	217.40	-0.28 %	K V
ABB	48.63	-1.26 %	K V
UBS Group	29.30	-1.61 %	K V
Lonza Grp	544.40	-1.73 %	K V
Part Grp Hldg	1’281.00	-2.66 %	K V
Holcim	84.32	-3.83 %	K V

mehr

22.08.24		Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen
22.08.24		Ausblick: Bavarian Nordic legt Quartalsergebnis vor
20.08.24		Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an
23.08.22		Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

22.08.24

Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen

22.08.24

Ausblick: Bavarian Nordic legt Quartalsergebnis vor

20.08.24

Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an

23.08.22

Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bavarian Nordic A/S

Aktien Top/Flop

Bavarian Nordic Peer Group Nachrichten

Meistgelesene Nachrichten